Imatib 400 mg contains imatinib, a targeted oral cancer therapy that has revolutionised the treatment of certain blood and gastrointestinal cancers. It is primarily used in conditions where abnormal cells multiply due to specific genetic mutations. Imatinib is known for its precision in targeting cancer-causing proteins while sparing healthy cells, making it more tolerable than traditional chemotherapy. It is considered a first-line treatment in many cases of chronic myeloid leukemia and gastrointestinal stromal tumors.

Mechanism of Action

Imatinib works by blocking specific tyrosine kinases, which are enzymes responsible for the growth and survival of cancer cells. In particular, it targets the BCR-ABL fusion protein that is present in most cases of chronic myeloid leukemia. By inhibiting this abnormal protein, imatinib prevents the uncontrolled growth of white blood cells. It also targets other kinases like c-KIT and PDGFR, which are implicated in gastrointestinal stromal tumors and certain other cancers.

Uses

Imatib is used to treat the following conditions:

• Chronic myeloid leukemia (CML) in all phases

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

• Gastrointestinal stromal tumors (GISTs)

• Myelodysplastic and myeloproliferative diseases

• Hypereosinophilic syndrome and chronic eosinophilic leukemia

• Dermatofibrosarcoma protuberans, a rare skin cancer

• Systemic mastocytosis, in selected cases

  Adverse Effects

  Common side effects

  • Nausea or vomiting

  • Muscle cramps or joint pain

  • Diarrhea

  • Fluid retention, including swelling around the eyes or ankles

  • Fatigue

  • Rash or skin irritation